Key Points of Emphasis Regarding Biosimilar Integration

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

Now Viewing

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

In final thoughts, Bincy Abraham, MD, MS, said biosimilars are coming and providers should gain confidence through knowledge to educate patients. Hopefully biosimilars reduce societal health care costs and patient costs.

Jamie T. Brogan, APRN, emphasized being confident in biosimilar data, utilizing resources to maintain access, and educating patients and staff.

Alice B. Gottlieb, MD, PhD, said educating prescribers is important for comfort with biosimilars. Payers and pharmacy benefit managers must put patients first and focus on lowering patient costs and improving access.

Vibeke Strand, MD, has confidence in biosimilar efficacy, safety, and immunogenicity. Interchangeability is less important as more biosimilars become available. However, expected cost savings have not reached patients because of system issues. Payers and pharmacy benefit managers must help translate savings to improve patient affordability.

Ryan Haumschild, PharmD, MS, MBA, said closer collaboration between stakeholders is needed to focus on patient interests.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.